Thailand Greenlights Zoliflodacin as Multi-Drug Resistant Gonorrhoea Threat Escalates
The Thai FDA has approved Nuzolvence, a pioneering oral antibiotic designed to combat uncomplicated urogenital gonorrhoea. This decision positions Thailand as the second global market to authorize the drug following its U.S. debut.
Regulatory Breakthrough for Antimicrobial Resistance
Thailand’s Food and Drug Administration has authorized the use of Nuzolvence (zoliflodacin), marking a major shift in the clinical management of uncomplicated urogenital gonorrhoea. The approval targets both standard infections and increasingly common multidrug-resistant strains. This regulatory milestone follows a priority review submission spearheaded by Dr. Reddy’s Laboratories, supported by the Global Antibiotic Research and Development Partnership (GARDP) Foundation.
The move comes six months after the U.S. Food and Drug Administration granted its own approval for the new chemical entity. As the second nation to clear the drug, Thailand serves as a critical entry point for this treatment in the Southeast Asian region.
A Public-Private Development Framework
Zoliflodacin originated through the research efforts of AstraZeneca before evolving under a comprehensive public-private partnership. Key stakeholders in bringing the drug to market include:
- Innoviva Specialty Therapeutics: A subsidiary of Innoviva Inc. that managed the development process.
- Dr. Reddy’s Laboratories: The entity leading regulatory engagements and submissions in Thailand.
- Aurigene Pharmaceutical Services (APSL): A Dr. Reddy’s subsidiary that provided essential product development support.
- GARDP: The organization responsible for facilitating access in low- and middle-income territories.
Deepak Sapra, CEO of API and Services at Dr. Reddy’s, noted that this approval ensures timely access to innovation for patients facing resistant bacterial strains. Peter Beyer, Deputy Executive Director of GARDP, stated that the certification validates the foundation’s specific antibiotic research and development model.
Global Market and Distribution Rights
The commercial landscape for zoliflodacin is divided by geography to balance profitability with global health equity. While Innoviva maintains commercial control over North American and European Union markets, GARDP secures the rights to register and sell the antibiotic in over 75% of the world's countries. This arrangement specifically targets the needs of developing economies where the burden of antibiotic-resistant sexually transmitted infections is often highest.
Source: The Hindu — Business
